Endocrine Abstracts

Introduction: Acromegaly is a rare, serious disease caused by the presence of a pituitary adenoma secreting an excessive amount of growth hormone (GH), which leads to a consequent increase in circulating insulin-like growth factor-1 (IGF-1) levels, and excessive skeletal growth and soft tissue enlargement. It is usually managed by surgery and/or treatment with somatostatin analogs (SSA). The ACRONIS study (CSOM230CIC05) will provide real-world evidence on the efficacy and safe...

Acromegaly is a morbid condition mainly caused by overproduction of growth-hormone (GH) from a pituitary adenoma leading to excessive growth. Normalisation of insulin-like growth factor-1 (IGF1) is an important goal for the treatment of acromegaly. The second-generation somatostatin analog (SSA) long acting pasireotide (la-PAS) has recently been introduced for the management of patients uncontrolled by first-generation SSA. The ACRONIS study (CSOM230CIC05) will provide real-wo...